rhuMAb VEGF (Bevacizumab)

DRUG2 trials

Sponsors

Genentech, Inc.

Conditions

Breast CancerRenal Cell Cancer

Phase 3

Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma

WithdrawnNCT00061178

Genentech, Inc.Renal Cell Cancer

Updated: 2016-10-19

A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast Cancer

CompletedNCT00109239

Genentech, Inc.Breast Cancer

Start: 2000-11-30End: 2002-09-30Updated: 2014-06-18